{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:47:24Z","timestamp":1776998844311,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,4,4]],"date-time":"2010-04-04T00:00:00Z","timestamp":1270339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00280-010-1299-8","type":"journal-article","created":{"date-parts":[[2010,4,3]],"date-time":"2010-04-03T07:06:31Z","timestamp":1270278391000},"page":"395-403","source":"Crossref","is-referenced-by-count":51,"title":["Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer"],"prefix":"10.1007","volume":"66","author":[{"given":"Emmanuel","family":"Mitry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebl","family":"Deplanque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Mornex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Moussy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Kinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rougier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,4]]},"reference":[{"key":"1299_CR1","unstructured":"American Cancer Society (2008) Cancer facts and figures\u00a02008. American Cancer Society, Atlanta. http:\/\/www.cancer.org:downloads\/STT\/2008CAFFfinalsecured.pdf"},{"issue":"13","key":"1299_CR2","first-page":"1558","volume":"21","author":"KB Wisinski","year":"2007","unstructured":"Wisinski KB, Wahl AO, Small W Jr, Benson AB III (2007) Inoperable pancreatic cancer: standard of care. Oncology (Williston Park) 21(13):1558\u20131564 (discussion 1565, 1570\u20131572)","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"1299_CR3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/gut.2006.113068","volume":"56","author":"P Ghaneh","year":"2007","unstructured":"Ghaneh P, Costello E, Neoptolemos J (2007) Biology and management of pancreatic cancer. Gut 56(8):1134\u20131152. doi: 10.1136\/gut.2006.103333","journal-title":"Gut"},{"key":"1299_CR4","unstructured":"Saif MW (2008) Is there a standard of care for the management of advanced pancreatic cancer? Highlights from the gastrointestinal cancers symposium. Orlando, FL, USA. Jan 25\u201327, 2008. JOP 9(2):91\u201398. doi: v09i02a02[pii]"},{"issue":"43","key":"1299_CR5","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.3748\/wjg.v12.i43.6973","volume":"12","author":"DR Xie","year":"2006","unstructured":"Xie DR, Liang HL, Wang Y, Guo SS, Yang Q (2006) Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 12(43):6973\u20136981","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1299_CR6","first-page":"337","volume":"7","author":"MW Saif","year":"2006","unstructured":"Saif MW (2006) Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006. JOP 7(4):337\u2013348. doi: v07i04a02[pii]","journal-title":"JOP"},{"issue":"6","key":"1299_CR7","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403\u20132413","journal-title":"J Clin Oncol"},{"issue":"15","key":"1299_CR8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960\u20131966. doi: JCO.2006.07.9525[pii]10.1200\/JCO.2006.07.9525","journal-title":"J Clin Oncol"},{"issue":"17","key":"1299_CR9","first-page":"6534","volume":"9","author":"RF Hwang","year":"2003","unstructured":"Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ (2003) Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9(17):6534\u20136544","journal-title":"Clin Cancer Res"},{"issue":"80","key":"1299_CR10","first-page":"2203","volume":"54","author":"W Kimura","year":"2007","unstructured":"Kimura W, Ma J, Takeshita A, Yamamoto T, Moriya T, Hirai I, Fuse A (2007) Analysis of c-kit protein expression in pancreatic neoplasms and its implication for prognosis. Hepatogastroenterology 54(80):2203\u20132208","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"1299_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ijc.2910620507","volume":"62","author":"M Ebert","year":"1995","unstructured":"Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, Korc M (1995) Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 62(5):529\u2013535","journal-title":"Int J Cancer"},{"issue":"2","key":"1299_CR12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00268-005-0165-z","volume":"30","author":"K Furuyama","year":"2006","unstructured":"Furuyama K, Doi R, Mori T, Toyoda E, Ito D, Kami K, Koizumi M, Kida A, Kawaguchi Y, Fujimoto K (2006) Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg 30(2):219\u2013226. doi: 10.1007\/s00268-005-0165-z","journal-title":"World J Surg"},{"issue":"4","key":"1299_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1023\/A:1023725029589","volume":"22","author":"V Gabarra-Niecko","year":"2003","unstructured":"Gabarra-Niecko V, Schaller MD, Dunty JM (2003) FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 22(4):359\u2013374","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"1299_CR14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.surg.2003.10.017","volume":"135","author":"MS Duxbury","year":"2004","unstructured":"Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 135(5):555\u2013562. doi: 10.1016\/j.surg.2003.10.017S0039606003006536[pii]","journal-title":"Surgery"},{"issue":"3","key":"1299_CR15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.bbrc.2003.10.060","volume":"311","author":"MS Duxbury","year":"2003","unstructured":"Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE (2003) RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 311(3):786\u2013792. doi: S0006291X03021478[pii]","journal-title":"Biochem Biophys Res Commun"},{"issue":"33","key":"1299_CR16","doi-asserted-by":"crossref","first-page":"23439","DOI":"10.1016\/S0021-9258(18)35853-8","volume":"267","author":"L Kornberg","year":"1992","unstructured":"Kornberg L, Earp HS, Parsons JT, Schaller M, Juliano RL (1992) Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 267(33):23439\u201323442","journal-title":"J Biol Chem"},{"issue":"5","key":"1299_CR17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35010517","volume":"2","author":"DJ Sieg","year":"2000","unstructured":"Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2(5):249\u2013256. doi: 10.1038\/35010517","journal-title":"Nat Cell Biol"},{"key":"1299_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1749-6632.1999.tb09515.x","volume":"880","author":"H Friess","year":"1999","unstructured":"Friess H, Guo XZ, Nan BC, Kleeff O, Buchler MW (1999) Growth factors and cytokines in pancreatic carcinogenesis. Ann N Y Acad Sci 880:110\u2013121","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"1299_CR19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bcp.2006.08.011","volume":"73","author":"MJ Nimwegen van","year":"2007","unstructured":"van Nimwegen MJ, van de Water B (2007) Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 73(5):597\u2013609. doi: S0006-2952(06)00505-3[pii]10.1016\/j.bcp.2006.08.011","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"1299_CR20","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcibr0801519","volume":"358","author":"TC Theoharides","year":"2008","unstructured":"Theoharides TC (2008) Mast cells and pancreatic cancer. N Engl J Med 358(17):1860\u20131861","journal-title":"N Engl J Med"},{"issue":"6","key":"1299_CR21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","volume":"22","author":"K Hahn","year":"2008","unstructured":"Hahn K, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22(6):1301\u20131309. doi: JVIM190[pii]10.1111\/j.1939-1676.2008.0190.x","journal-title":"J Vet Intern Med"},{"key":"1299_CR22","doi-asserted-by":"crossref","unstructured":"Bui BN, Blay JY, Duffaud F, Hermine O, Hermine O, Le Cesne A (2007) Preliminary efficacy and safety results of masitinib administered front line in patients with advanced GIST\u2014a phase 2 study. J Clin Oncol ASCO Ann Meet Proc Part I 25 No 18S(Suppl 20):10025","DOI":"10.1200\/jco.2007.25.18_suppl.10025"},{"issue":"13","key":"1299_CR23","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ejca.2009.05.010","volume":"45","author":"JC Soria","year":"2009","unstructured":"Soria JC, Massard C, Magne N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP (2009) Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and\/or metastatic solid cancers. Eur J Cancer 45(13):2333\u20132341. doi: 10.1016\/j.ejca.2009.05.010","journal-title":"Eur J Cancer"},{"issue":"3","key":"1299_CR24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1299_CR25","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T","volume":"85","author":"AM Storniolo","year":"1999","unstructured":"Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261\u20131268","journal-title":"Cancer"},{"issue":"1","key":"1299_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(07)70383-2","volume":"9","author":"S Cascinu","year":"2008","unstructured":"Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A (2008) Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 9(1):39\u201344. doi: S1470-2045(07)70383-2[pii]10.1016\/S1470-2045(07)70383-2","journal-title":"Lancet Oncol"},{"key":"1299_CR27","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.ejca.2006.03.029","volume":"42","author":"M Glabbeke Van","year":"2006","unstructured":"Van Glabbeke M, Verweij J, Casali PG et al (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42:2277\u20132285","journal-title":"Eur J Cancer"},{"key":"1299_CR28","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar2740","volume":"11","author":"J Tebib","year":"2009","unstructured":"Tebib J, Mariette X, Bourgeois P et al (2009) Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 11:R95","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1299_CR29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/sj.bjc.6604983","volume":"100","author":"F Kullmann","year":"2009","unstructured":"Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gabele E, Hinke A, Hollerbach C, Endlicher E (2009) Cetuximab plus gemcitabine\/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 100(7):1032\u20131036. doi: 6604983[pii]10.1038\/sj.bjc.6604983","journal-title":"Br J Cancer"},{"issue":"5","key":"1299_CR30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10637-008-9127-2","volume":"26","author":"AH Ko","year":"2008","unstructured":"Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA (2008) A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 26(5):463\u2013471. doi: 10.1007\/s10637-008-9127-2","journal-title":"Invest New Drugs"},{"issue":"15","key":"1299_CR31","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","volume":"23","author":"C Louvet","year":"2005","unstructured":"Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15):3509\u20133516. doi: 23\/15\/3509[pii]10.1200\/JCO.2005.06.023","journal-title":"J Clin Oncol"},{"issue":"7","key":"1299_CR32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jjco\/hym060","volume":"37","author":"H Ueno","year":"2007","unstructured":"Ueno H, Okusaka T, Ikeda M, Morizane C, Ogura T, Hagihara A, Tanaka T (2007) Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. Jpn J Clin Oncol 37(7):515\u2013520. doi: hym060[pii]10.1093\/jjco\/hym060","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1299_CR33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.mcg.0000225657.30803.9d","volume":"42","author":"JK Park","year":"2008","unstructured":"Park JK, Yoon YB, Kim YT, Ryu JK, Yoon WJ, Lee SH (2008) Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 42(1):86\u201391. doi: 10.1097\/01.mcg.0000225657.30803.9d00004836-200801000-00017[pii]","journal-title":"J Clin Gastroenterol"},{"issue":"19","key":"1299_CR34","first-page":"5476","volume":"62","author":"K Pietras","year":"2002","unstructured":"Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62(19):5476\u20135484","journal-title":"Cancer Res"},{"issue":"7","key":"1299_CR35","first-page":"2929","volume":"61","author":"K Pietras","year":"2001","unstructured":"Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61(7):2929\u20132934","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1299-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1299-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T13:36:25Z","timestamp":1635168985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1299-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1299-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,4]]}}}